Paul F. Truex Purchases 5,000 Shares of Milestone Pharmaceuticals Inc. (NASDAQ:MIST) Stock

Milestone Pharmaceuticals Inc. (NASDAQ:MISTGet Rating) Director Paul F. Truex bought 5,000 shares of Milestone Pharmaceuticals stock in a transaction on Tuesday, May 31st. The stock was acquired at an average cost of $5.60 per share, with a total value of $28,000.00. Following the acquisition, the director now owns 81,780 shares in the company, valued at approximately $457,968. The purchase was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this link.

MIST traded down $0.18 during midday trading on Wednesday, hitting $5.43. 16,610 shares of the company were exchanged, compared to its average volume of 84,912. Milestone Pharmaceuticals Inc. has a 1-year low of $3.98 and a 1-year high of $8.24. The firm has a market capitalization of $162.49 million, a price-to-earnings ratio of -5.17 and a beta of 3.11. The company’s 50 day simple moving average is $6.35 and its 200 day simple moving average is $6.28.

Milestone Pharmaceuticals (NASDAQ:MISTGet Rating) last issued its quarterly earnings results on Thursday, May 12th. The company reported ($0.33) earnings per share for the quarter, beating analysts’ consensus estimates of ($0.39) by $0.06. On average, research analysts anticipate that Milestone Pharmaceuticals Inc. will post -1.44 EPS for the current fiscal year.

Several analysts recently commented on MIST shares. HC Wainwright reaffirmed a “buy” rating on shares of Milestone Pharmaceuticals in a report on Tuesday, March 29th. Piper Sandler raised Milestone Pharmaceuticals from a “neutral” rating to an “overweight” rating and boosted their price objective for the stock from $8.00 to $10.00 in a research note on Thursday, April 21st. Finally, Zacks Investment Research cut Milestone Pharmaceuticals from a “hold” rating to a “sell” rating in a research note on Wednesday, March 30th.

Several hedge funds and other institutional investors have recently made changes to their positions in the company. BNP Paribas Arbitrage SA acquired a new position in shares of Milestone Pharmaceuticals in the first quarter worth $25,000. JPMorgan Chase & Co. acquired a new position in shares of Milestone Pharmaceuticals in the fourth quarter worth $46,000. PDT Partners LLC acquired a new position in shares of Milestone Pharmaceuticals in the first quarter worth $65,000. Acadian Asset Management LLC grew its stake in shares of Milestone Pharmaceuticals by 63.0% in the fourth quarter. Acadian Asset Management LLC now owns 12,381 shares of the company’s stock worth $79,000 after acquiring an additional 4,785 shares in the last quarter. Finally, National Bank of Canada FI acquired a new position in shares of Milestone Pharmaceuticals in the fourth quarter worth $96,000. Institutional investors and hedge funds own 67.65% of the company’s stock.

Milestone Pharmaceuticals Company Profile (Get Rating)

Milestone Pharmaceuticals Inc, a biopharmaceutical company, focuses on the development and commercialization of cardiovascular medicines. The company is developing etripamil, a novel channel blocker, which is in Phase III clinical trial for the treatment of paroxysmal supraventricular tachycardia in the United States and Canada; and Phase II clinical trial for the treatment of atrial fibrillation and rapid ventricular rate.

Recommended Stories

Receive News & Ratings for Milestone Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Milestone Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.